Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
-
Andreas Deussen
Abstract
Homocysteine may have deleterious effects on the cardiovascular system. It has been hypothesized that these effects may be brought about by a decrease in the adenosine concentration via the S-adenosylhomocysteine hydrolase reaction. A requirement for this causal relationship is proof of a reduction in vascular adenosine concentration during conditions of elevated homocysteine concentrations. In the present communication we summarize published data obtained during systematic variation of the arterial homocysteine concentration. Most of the results reported show that an increase in homocysteine concentration to 100μM is associated with a 20–50% decrease in vascular adenosine concentration and an increase in tissue S-adenosylhomocysteine level. Homocysteine effects on the adenosine concentration seem to be more pronounced under conditions of impaired oxygenation. Further experiments, in particular on organs and tissue that release high amounts of homocysteine, i.e., the liver, are warranted to study the potential effects of homocysteine on vascular and tissue adenosine concentrations and consequent effects on organ function. The evidence obtained may be relevant for future assessment of risk indicators in conjunction with homocysteine pathogenicity, which might potentially be extended to measurements of adenosine or S-adenosylhomocysteine levels.
References
1. Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32:73–97.10.1016/0033-0620(89)90015-7Suche in Google Scholar
2. Lasley RD, Mentzer RM Jr. Protective effects of adenosine in the reversibly injured heart. Ann Thorac Surg 1995; 60:843–6.10.1016/0003-4975(95)00332-FSuche in Google Scholar
3. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22:364–73.10.1161/hq0302.105360Suche in Google Scholar
4. Stein AB, Tang XL, Guo Y, Xuan YT, Dawn B, Bolli R. Delayed adaptation of the heart to stress: late preconditioning. Stroke 2004; 35(Suppl 1):2676–9.10.1161/01.STR.0000143220.21382.fdSuche in Google Scholar
5. Deussen A, Stappert M, Schäfer S, Kelm M. Quantification of extracellular and intracellular adenosine production. Understanding the transmembranous concentration gradient. Circulation 1999; 99:2041–7.10.1161/01.CIR.99.15.2041Suche in Google Scholar
6. Riksen NP, Rongen GA, Blom HJ, Russel FG, Boers GH, Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003; 59:271–6.10.1016/S0008-6363(03)00462-0Suche in Google Scholar
7. Schrader J, Schütz W, Bardenheuer H. Role of S-adenosylhomocysteine hydrolase in adenosine metabolism in mammalian heart. Biochem J 1981; 196:65–70.10.1042/bj1960065Suche in Google Scholar
8. Achterberg PW, de Tombe PP, Harmsen E, de Jong JW. Myocardial S-adenosylhomocysteine hydrolase is important for adenosine production during normoxia. Biochim Biophys Acta 1985; 840:393–400.10.1016/0304-4165(85)90220-XSuche in Google Scholar
9. Deussen A, Borst M, Schrader J. Formation of S-adenosylhomocysteine in the heart. I: an index of free intracellular adenosine. Circ Res 1988; 63:240–9.10.1161/01.RES.63.1.240Suche in Google Scholar PubMed
10. Kroll K, Deussen A, Sweet IR. Comprehensive model of transport and metabolism of adenosine and S-adenosylhomocysteine in the guinea pig heart. Circ Res 1992; 71:590–604.10.1161/01.RES.71.3.590Suche in Google Scholar
11. Chen YF, Li PL, Zou AP. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 2002; 106:1275–81.10.1161/01.CIR.0000027586.64231.1BSuche in Google Scholar
12. Riksen NP, Rongen GA, Boers GH, Blom HJ, van den Broek PH, Smits P. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2005; 25:109–14.10.1161/01.ATV.0000150651.85907.69Suche in Google Scholar
13. Sciotti VM, van Wylen DG. Attenuation of ischemia-induced extracellular adenosine accumulation by homocysteine. J Cereb Blood Flow Metab 1993; 13:208–13.10.1038/jcbfm.1993.25Suche in Google Scholar
14. Henrichs KJ, Matsuoka H, Schaper J. Intracellular trapping of adenosine during myocardial ischemia by L-homocysteine. Basic Res Cardiol 1986; 81:267–75.10.1007/BF01907409Suche in Google Scholar
15. Kloor D, Delabar U, Muhlbauer B, Luippold G, Osswald H. Tissue levels of S-adenosylhomocysteine in the rat kidney: effects of ischemia and homocysteine. Biochem Pharmacol 2002; 63:809–15.10.1016/S0006-2952(01)00892-9Suche in Google Scholar
16. Feelisch M, Te Poel M, Zamora R, Deussen A, Moncada S. Understanding the controversy over the identity of EDRF. Nature 1994; 368:62–5.10.1038/368062a0Suche in Google Scholar PubMed
17. Loncar R, Flesche C, Deussen A. Coronary reserve of high- and low-flow regions in the dog heart left ventricle. Circulation 1998; 98:262–70.10.1161/01.CIR.98.3.262Suche in Google Scholar
©2005 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Homocysteine research – where do we stand and where are we going?
- Hyperhomocysteinemia and arteriosclerosis: historical perspectives
- Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
- Homocysteine and vascular disease in diabetes: a double hit?
- Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
- Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
- Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
- Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
- Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
- Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
- Hyperhomocysteinemia and macromolecule modifications in uremic patients
- Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
- Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
- Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
- Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
- A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
- Betaine: a key modulator of one-carbon metabolism and homocysteine status
- Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
- Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
- Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
- Homocysteine and B vitamins in mild cognitive impairment and dementia
- Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
- Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
- Homocysteine – a newly recognised risk factor for osteoporosis
- Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
- Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
- Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
- Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
- Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
- Interactions between folate and aging for carcinogenesis
- The potential cocarcinogenic effect of vitamin B12 deficiency
- The vegetarian lifestyle and DNA methylation
Artikel in diesem Heft
- Homocysteine research – where do we stand and where are we going?
- Hyperhomocysteinemia and arteriosclerosis: historical perspectives
- Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
- Homocysteine and vascular disease in diabetes: a double hit?
- Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
- Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
- Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
- Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
- Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
- Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
- Hyperhomocysteinemia and macromolecule modifications in uremic patients
- Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
- Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
- Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
- Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
- A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
- Betaine: a key modulator of one-carbon metabolism and homocysteine status
- Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
- Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
- Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
- Homocysteine and B vitamins in mild cognitive impairment and dementia
- Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
- Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
- Homocysteine – a newly recognised risk factor for osteoporosis
- Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
- Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
- Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
- Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
- Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
- Interactions between folate and aging for carcinogenesis
- The potential cocarcinogenic effect of vitamin B12 deficiency
- The vegetarian lifestyle and DNA methylation
